AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03472625 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Screening and diagnosis of aphasia, dysarthria, dysphagia
Description: Screening (day 2 +/- 1; day 7 +/-1): NIHSS (National Health Institute Scale) 9 and 10 scores, dysphagia screening (nurse), speech-, and language screening (speech therapist)~Diagnostic assessment (day 2 +/-1-):~Dysphagia: MASA (Mann Assessment of Swallowing Abilities), FOIS (Functional Oral Intake Scale) Dysarthria: perceptual assessment, NSVO-Z (Nederlands spraakverstaanbaarheidsonderzoek - zinnen) Aphasia: ScreeLing, BNT (Boston Naming Test)
Study NCT00579774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low AGE Diet
Description: Diet
Study NCT01621737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 84 IU BID for six weeks
Study NCT01621737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle placebo
Study NCT00641901 — intervention group
Intervention type: BEHAVIORAL
Intervention: counseling
Description: The 8-week study includes 3 visits to the dental facility at the Center for Women's Reproductive Health at UAB. Study visits are scheduled to coincide with pre-natal visits in the same facility.~Each visit will include individually tailored one-to-one discussion with a dental professional coupled with a demonstration and instructions for using oral hygiene products. Home-care kits will be dispensed, to include a helpful digital video disk (DVD), a high-tech powered toothbrush, dental floss, toothpaste and alcohol-free mouth rinse and subjects will have their teeth professionally cleaned.~First and final visits will include collection of gingival crevicular fluid and blood samples and subjects will complete pre and post study questionnaires.
Study NCT03910686 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation and cognitive behavioral therapy
Description: Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
Study NCT00579774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Diet
Description: Diet
Study NCT02568969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eirus continuous lactate monitor
Description: a triple-lumen central venous catheter (Eirus TLC) functioning as a regular central venous catheter (CVC) with an integrated microdialysis function will be inserted via the left jugular vein for continuous monitoring of lactate and glucose using Eirus intravascular microdialysis system (Maquet Critical Care, Solna, Sweden) after calibration with arterial sample. Eirus TLC will be used for both drug administration and blood sampling and will be removed postoperatively when a central line will no longer be necessary.
Study NCT03424564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral Tablet
Study NCT01589796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: injection of 20ml of Ropivacaine 0.5% in the proper place once it is identified
Study NCT00005984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: intravenously over 2 hours on day 1 and on days -7 and -6
Study NCT00005984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: filgrastim (G-CSF) daily subcutaneously (SQ) starting on day 5 and continuing until completion of leukapheresis. Patients also receive G-CSF IV starting on day 0 and continuing until blood counts recover
Study NCT00005984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: Beginning on Day 1, subcutaneous (SQ) daily administration in the absence of unacceptable toxicity or disease progression
Study NCT00005984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Patients receive the PBSC transplantation on day 0.
Study NCT00005984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: total body irradiation twice a day on days -4 through -1
Study NCT01254253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention, PCI
Description: PCI was performed using standard techniques for CTO.
Study NCT03646604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib (ABT-494)
Description: Upadacitinib will be administered orally.
Study NCT03910686 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial magnetic stimulation and cognitive behavioral therapy
Description: Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
Study NCT04393337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gestational Age Chart Method
Description: The endotracheal tube insertion depth is obtained by the gestational age chart
Study NCT04393337 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal-Tragus Length Method
Description: The endotracheal tube insertion depth is obtained by the nasal-tragus method formula
Study NCT00414635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermitent Dosing
Description: Intermittent dosing treatment is the maintenance of the 5/2 schedule, where the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed for 5 consecutive days - typically Monday through Friday - followed by two days off of medication, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine. .
Study NCT00414635 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intermitent Dosing
Description: Intermittent dosing treatment is the maintenance of the 5/2 schedule, where the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed for 5 consecutive days - typically Monday through Friday - followed by two days off of medication, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine. .
Study NCT03534609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutronic Genius System
Description: Treatment of the neck using the Lutronic Genius System
Study NCT00991861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41007 o.d.
Description: Once daily, topical application
Study NCT00991861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41007 b.i.d.
Description: Twice daily, topical application
Study NCT00991861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS106521
Description: Twice daily, topical application
Study NCT04301375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab and trastuzumab FDC subcutaneous
Description: Pertuzumab and trastuzumab FDC subcutaneous, A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg; day 1 of each 3 week cycle during 5 neoadjuvant cycles and 13 adjuvant cycles if complete response
Study NCT04301375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2, day 1,8,15 of each 3 week cycle during 4 cycles
Study NCT04301375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM1
Description: 3,6 mg/kg, 14 adjuvant cycles if not complete response
Study NCT04301375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Adjuvant endocrine therapy will be administered as per local practice and according to recognized clinical practice guidelines
Study NCT04301375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission surgery
Description: Omission of surgery and sentinel lymph node dissection in patients with HER2-E and ERBB2 high breast cancer who achieving a complete response following standard anti-HER2-based neoadjuvant therapy with paclitaxel/trastuzumab/pertuzumab
Study NCT04107948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity program
Description: Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42), Haute-Loire (43) or Ardèche (07) for 2 months.
Study NCT04107948 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Advice and recommendations of physical activity at home
Description: Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
Study NCT03010917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish Oil with ethanol and placebo ethanol infusions
Description: Fish Oil with ethanol and placebo ethanol infusions
Study NCT03010917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with ethanol and placebo ethanol infusions
Description: Placebo with ethanol and placebo ethanol infusions
Study NCT02474446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 150,000 IU of Vitamin D3 Oral solution
Study NCT00777140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.~Bolus + 72h perfusion of saline solution for the placebo group.
Study NCT00777140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deferoxamine
Description: Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.~Bolus + 72h perfusion of saline solution for the placebo group.
Study NCT00659412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Intramuscular
Study NCT00659412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral
Study NCT00659412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral
Study NCT00659412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular
Study NCT02946437 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: Postconditioning with sevoflurane (0.5-1.5vol%) for 4 hours after coiling or clipping of cerebral aneurysm in patients with severe SAH
Study NCT02946437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Postconditioning with sevoflurane (0.5-1.5vol%) for 4 hours after coiling or clipping of cerebral aneurysm in patients with severe SAH
Study NCT02946437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
Study NCT02946437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
Study NCT02946437 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MIRUS™System
Description: The MIRUS™System is the normally used standard equipment for the administration of volatile anaesthetics to patients.
Study NCT02946437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRUS™System
Description: The MIRUS™System is the normally used standard equipment for the administration of volatile anaesthetics to patients.
Study NCT00003994 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection
Study NCT00003994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00003994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00003994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00003994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: Given IV
Study NCT00003994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT02423850 — intervention group
Intervention type: DEVICE
Intervention: 3D Wound Assessment Monitor (WAM) camera
Description: Three-dimensional wound measurement (2D area, 3D area, perimeter, volume) using 3D-WAM camera
Study NCT04683627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium active topical patch
Description: A topical patch with diclofenac sodium as active ingredient was used and evaluated for the treatment of OA pain of the knee.
Study NCT04683627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: A placebo patch without diclofenac sodium was used for the placebo arm.
Study NCT01820299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract
Description: All patients enrolled to the study will take Grape Seed Extract alone for 21 days.
Study NCT01820299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: From Day 22 until Day 64 of the study, patients will take Grape Seed Extract and Vitamin D together. Patients will take Vitamin D once at a day at 4000 IU.
Study NCT00656357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SYN117 Placebo
Description: Placebo
Study NCT00656357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN117 80 mg
Description: SYN117 80 mg
Study NCT00656357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN117 160 mg
Description: SYN117 160 mg
Study NCT00656357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine 10mg
Description: IV Cocaine 10mg
Study NCT00656357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 10mg
Description: IV Cocaine 10mg
Study NCT00656357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine 20mg
Description: IV Cocaine 20mg
Study NCT00656357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 20mg
Description: IV Cocaine 20mg
Study NCT00656357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine 40mg
Description: IV Cocaine 40mg
Study NCT00656357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 40mg
Description: IV Cocaine 40mg
Study NCT00656357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: IV Cocaine Placebo
Study NCT00656357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: IV Cocaine Placebo
Study NCT01179724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose proton pump inhibitor
Description: IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month
Study NCT01179724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H2RB
Description: IV 50mg loading H2 receptor antagonist before 2hr to conduct ESD, and IV 13mg/h continuous infusion within 48hr, and then 300mg oral H2 receptor antagonist for one month
Study NCT04427319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-alanine
Description: 7 days of consumption
Study NCT04427319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: wheat semolina
Description: 7 days of consumption
Study NCT03623113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCC intervention
Description: Structured training and education i basic carbohydrate counting principles
Study NCT03623113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABC-ACC intervention
Description: Structured training and education i advanced carbohydrate counting principles including the use of a automated bolus calculator carbohydrate
Study NCT03623113 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dietary education
Description: Personalized individual dietary counselling based on overall meal planning, dietary guidelines and the patient's need and preferences
Study NCT03866070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Two exercises will be done to strengthen the external rotation (using elastic bands): standing with 90 degrees of shoulder abduction and elbow flexion and also in standing with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. Dumbbell exercises will be performed through 4 exercises: flexion in the horizontal plane of 135º, external rotation in lateral decubitus, horizontal abduction with external rotation, and extension in prone position. There will be 5 repetitions each exercise of 3 seconds each, with 2 minutes of rest between exercises.
Study NCT03866070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Two exercises will be done to strengthen the external rotation, using elastic bands. The first, standing, with 90 degrees of shoulder abduction and elbow flexion. The second, also in standing, with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. The band will be subject to a surface, at an equal distance from the subject's elbow to the ground. The repetitions will last one second in concentric external rotation and two seconds in eccentric external rotation, with a rest of 30 seconds between series.
Study NCT04333563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Continuous positive airway pressure
Study NCT04333563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous positive airway pressure
Study NCT04333563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV NAVA
Description: Non-invasive neurally adjusted ventilatory assist
Study NCT04333563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV NAVA
Description: Non-invasive neurally adjusted ventilatory assist
Study NCT02564666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: telephone counseling
Description: regular telephone counseling for compliance and advese event
Study NCT05118971 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: muscle activation of the vastus lateralis, vastus medialis, gluteus medius, tibialis anterior, rectus abdominis and paravertebral muscles
Description: understand the pattern of muscle activation during modalities used in this study with the selected population, it becomes extremely important, allowing the quantification of muscle functions and, therefore, prescribing exercises more adequately to achieve therapeutic goals.
Study NCT02780401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02780401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
Description: Given ID
Study NCT02780401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given ID
Study NCT04004897 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optic nerve sheath diameter measurement
Description: Optic nerve sheath diameter measurement is performed with a linear ultrasound probe placed over the eyelid.
Study NCT04782401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided genicular nerve block + exercise treatment
Description: This method was used to inject a total of 6 mL of lidocaine plus 40 mg of triamcinolone (TA) at 3 separate target sites: the superior lateral, superior medial, and inferior medial genicular nerves plus exercise treatment
Study NCT04782401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy + exercise treatment
Description: Ten sessions of hotpack as a surface warmer, TENS as a analgezic current, ultrasound therapy as a deep warmer and exercise treatment.
Study NCT01776801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion
Description: Infusion studies are performed in daily clinical routine to measure cerebrospinal fluid resistance outflow. During this test ICP is slowly and securely raised. Investigators plan to analyze what are the consequences of this ICP rise in terms of autonomic system and hemodynamics.
Study NCT02017197 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Marevan®
Description: Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.
Study NCT02017197 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: generic warfarin #1
Description: Generic warfarin sodium tablets, manufacturer (União Química Farmacêutica Nacional S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
Study NCT02017197 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: generic warfarin #2
Description: Generic warfarin sodium tablets, manufacturer (Laboratório Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.